00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
21:36 , Jan 26, 2018 |  BC Extra  |  Clinical News

After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease. The...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Boehringer and Anthem begin real-world COPD trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Anthem Inc. (NYSE:ANTM) with its outcomes research subsidiary HealthCore Inc. have begun enrolling patients in a real-world study evaluating the effect of Stiolto Respimat tiotropium/olodaterol on the occurrence of...
12:04 , Oct 5, 2017 |  BC Extra  |  Clinical News

Boehringer, Anthem begin real-world COPD trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Anthem Inc. (NYSE:ANTM) and its outcomes research subsidiary HealthCore Inc. have begun enrolling patients in a real-world study evaluating the effect of Stiolto Respimat tiotropium/olodaterol on the occurrence of...
20:17 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

GSK preparing submissions for Nucala in COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) plans to submit regulatory applications this half for Nucala mepolizumab (SB-240563) to treat chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype after reporting mixed data from the double-blind, international Phase...
17:32 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

Sanofi, Regeneron report Phase III asthma readout for Dupixent

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported top-line data from the Phase III LIBERTY ASTHMA QUEST trial in 1,902 patients with uncontrolled, persistent asthma showing that Dupixent dupilumab (REGN668, SAR231893) met the co-primary...
21:55 , Sep 11, 2017 |  BC Extra  |  Clinical News

Regeneron falls on Phase III asthma readout for Dupixent

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Dupixent dupilumab met the co-primary endpoints in the Phase III LIBERTY ASTHMA QUEST trial to treat uncontrolled, persistent asthma. However, the data failed to impress investors...
17:52 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

GSK, Innoviva seek expanded Relvar Ellipta label

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) submitted to EMA an application to expand the label for Relvar Ellipta fluticasone furoate/vilenterol (GW685698/GW64244) to treat patients whose asthma is already adequately controlled on an inhaled...
19:54 , May 12, 2017 |  BC Week In Review  |  Clinical News

AZ's tralokinumab misses in Phase III asthma trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said 300 mg tralokinumab (CAT-354) every 2 weeks missed the primary endpoint of reducing annual asthma exacerbation rate in the overall population vs. placebo in the Phase III STRATOS 1 trial...
21:21 , May 10, 2017 |  BC Extra  |  Clinical News

AZ's asthma candidate misses in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in the Phase III STRATOS 1 trial to treat severe uncontrolled asthma. Compared to placebo, the human IgG4 mAb against IL-13 did not significantly...